MA43042A - Composition aqueuse d'apomorphine pour une administration sous-cutanée - Google Patents

Composition aqueuse d'apomorphine pour une administration sous-cutanée

Info

Publication number
MA43042A
MA43042A MA043042A MA43042A MA43042A MA 43042 A MA43042 A MA 43042A MA 043042 A MA043042 A MA 043042A MA 43042 A MA43042 A MA 43042A MA 43042 A MA43042 A MA 43042A
Authority
MA
Morocco
Prior art keywords
apomorphine
aqueous composition
subcutaneous administration
subcutaneous
administration
Prior art date
Application number
MA043042A
Other languages
English (en)
Inventor
Kerstin Hartwig
Dieter Horst Meier
Sabine Schmidt
Heinz Schnait
Christian Seliger
Zoltán Tölgyesi
Original Assignee
Ever Neuro Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ever Neuro Pharma Gmbh filed Critical Ever Neuro Pharma Gmbh
Publication of MA43042A publication Critical patent/MA43042A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA043042A 2015-09-28 2016-09-28 Composition aqueuse d'apomorphine pour une administration sous-cutanée MA43042A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15187194 2015-09-28

Publications (1)

Publication Number Publication Date
MA43042A true MA43042A (fr) 2018-08-08

Family

ID=54249338

Family Applications (1)

Application Number Title Priority Date Filing Date
MA043042A MA43042A (fr) 2015-09-28 2016-09-28 Composition aqueuse d'apomorphine pour une administration sous-cutanée

Country Status (6)

Country Link
US (1) US20180280465A1 (fr)
EP (1) EP3355887A1 (fr)
AU (1) AU2016333486B2 (fr)
CA (1) CA2999675C (fr)
MA (1) MA43042A (fr)
WO (1) WO2017055337A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2979688A1 (fr) 2014-08-01 2016-02-03 Britannia Pharmaceuticals Limited Composition contenant de l'apomorphine et un cation de métal divalent
WO2023012736A1 (fr) * 2021-08-05 2023-02-09 Zydus Lifesciences Limited Compositions pharmaceutiques stables d'apomorphine
KR20240069750A (ko) * 2021-09-12 2024-05-20 지엠피 바이오테크놀로지 리미티드 신경 장애의 치료
WO2023172649A1 (fr) * 2022-03-11 2023-09-14 Alexza Pharmaceuticals, Inc. Triméthanolate de chlorhydrate d'apomorphine, ses polymorphes et ses utilisations
EP4540257A1 (fr) 2022-06-15 2025-04-23 EVER Neuro Pharma GmbH Promédicaments d'apomorphine et leurs utilisations
KR20250154980A (ko) * 2024-04-22 2025-10-29 연세대학교 산학협력단 세포 예정 괴사의 억제제로써의 화합물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6121276A (en) 1994-04-22 2000-09-19 Pentech Pharmaceuticals, Inc. Apomorphine-containing dosage forms for ameliorating male erectile dysfunction
US5562917A (en) 1994-12-23 1996-10-08 Pentech Pharmaceuticals, Inc. Transdermal administration of apomorphine
SE0102036D0 (sv) 2001-06-08 2001-06-08 Axon Biochemicals Bv Pharmaceutical formulation for the efficient administration of apomorphine, 6aR- (-) -N- Propyl- norapomorphine and their derivatives and pro-drugs thereof
GB0509317D0 (en) 2005-05-06 2005-06-15 Clarke Anthony Pharmaceutical formulation of apomorphine
GB0715285D0 (en) 2007-08-06 2007-09-12 Britannia Pharmaceuticals Ltd Improvements in or relating to powdered medicaments for nasal delivery
GB0721394D0 (en) 2007-10-31 2007-12-12 Vectura Group Plc Compositions for trating parkinson's disease
EP2545905A1 (fr) 2011-07-11 2013-01-16 Britannia Pharmaceuticals Limited Nouvelle composition thérapeutique contenant de l'apomorphine en tant que principe actif
EP2854764B1 (fr) * 2012-06-05 2018-12-12 Neuroderm Ltd Compositions comprenant de l'apomorphine et des acides organiques, et leurs utilisations

Also Published As

Publication number Publication date
AU2016333486A1 (en) 2018-04-19
WO2017055337A1 (fr) 2017-04-06
EP3355887A1 (fr) 2018-08-08
CA2999675A1 (fr) 2017-04-06
CA2999675C (fr) 2023-10-17
US20180280465A1 (en) 2018-10-04
AU2016333486B2 (en) 2022-02-03

Similar Documents

Publication Publication Date Title
MA41265A (fr) Compositions pour administration de médicaments iléo-jéjunal.
EP3607023C0 (fr) Solutions micellaires pour traitement de formations d'hydrocarbures
CR20160456A (es) Compuestos de heteroarilo o arilo bibíclicos fusionados
EP3431075C0 (fr) Forme galénique d'édaravone
EP3386981A4 (fr) Hétérocycles utiles en tant qu'agents anticancereux
MA40587A (fr) Composés d'aminopyrimidinyle en tant qu'inhibiteurs de jak
EP3013345A4 (fr) Composés pour le traitement d'une amyotrophie spinale
EP3463360A4 (fr) Composition aqueuse contenant de l'atropine
EP3342829A4 (fr) Encre d'héliogravure aqueuse
EP3318580A4 (fr) Composition d'émulsion aqueuse
DK3532029T3 (da) Flydende farmaceutisk sammensætning
LT3362049T (lt) Kamptotecino farmacinių kompozicijų stabilizavimas
LT3116491T (lt) Terapiškai aktyvių junginių farmacinės kompozicijos
EP3289026A4 (fr) Composition aqueuse de revêtement antitache
EP3345002A4 (fr) Sélection de patients pour une polythérapie
HUE040097T2 (hu) Folyékony gyógyszerészeti készítmény
EP2948134A4 (fr) Compositions pour une administration transdermique d'inhibiteurs de mtor
GB2548424B (en) Liquid pharmaceutical composition of clonidine
EP3590546A4 (fr) Composition pour injection cutanée
LT3419595T (lt) Stabili skysta gonadotropino kompozicija
EP3479828A4 (fr) Composition médicamenteuse pour administration parentérale
EP3355894A4 (fr) Composition pour le maintien de la dominance de lactobacillus
FR3020758B1 (fr) Composition pour ameliorer l'hygiene buco-dentaire
EP3277795A4 (fr) Compositions pour la production améliorée d'enzymes
EP3364979A4 (fr) Composition pour moduler irak1